

Sella Provan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/211724/sella-provan-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

815
citations

14
h-index

28
g-index

40
ext. papers

1,046
ext. citations

4.2
avg, IF

3.79
L-index

#	Paper	IF	Citations
35	Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. <i>Hypertension</i> , 2010 , 55, 333-8	8.5	122
34	Effect of 1-year anti-TNF- α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. <i>American Journal of Hypertension</i> , 2012 , 25, 644-50	2.3	108
33	Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 812-7	2.4	83
32	Carotid plaque characteristics and disease activity in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 359-68	4.1	71
31	Efficacy of high intensity exercise on disease activity and cardiovascular risk in active axial spondyloarthritis: a randomized controlled pilot study. <i>PLoS ONE</i> , 2014 , 9, e108688	3.7	63
30	Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016 , 43, 1622-30	4.1	39
29	The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tocilizumab. <i>PLoS ONE</i> , 2015 , 10, e0130709	3.7	39
28	Physical fitness in patients with ankylosing spondylitis: comparison with population controls. <i>Physical Therapy</i> , 2012 , 92, 298-309	3.3	36
27	Early prediction of increased arterial stiffness in patients with chronic inflammation: a 15-year followup study of 108 patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 606-12	4.1	33
26	NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1946-50	2.4	28
25	Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. <i>Journal of Rheumatology</i> , 2015 , 42, 645-53	4.1	27
24	CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1562-6	2.4	25
23	Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. <i>Lancet Rheumatology</i> , 2021 ,	14.2	15
22	Tender Joint Count and Inflammatory Activity in Patients With Established Rheumatoid Arthritis: Results From a Longitudinal Study. <i>Arthritis Care and Research</i> , 2020 , 72, 27-35	4.7	15
21	Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1179-1185	2.4	14
20	Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. <i>Rheumatology</i> , 2020 , 59, 505-512	3.9	13
19	Evidence of reduced parasympathetic autonomic regulation in inflammatory joint disease: A meta-analyses study. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 134-140	5.3	12

18	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. <i>RMD Open</i> , 2018 , 4, e000655	5.9	11
17	Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 116, 58-62	2.2	10
16	Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. <i>RMD Open</i> , 2019 , 5, e001079	5.9	9
15	Effects of a community-based multicomponent rehabilitation programme for patients with fibromyalgia: protocol for a randomised controlled trial. <i>BMJ Open</i> , 2018 , 8, e021004	3	7
14	One-year treatment outcomes of secukinumab versus tumor necrosis factor inhibitors in Spondyloarthritis. <i>Arthritis Care and Research</i> , 2020 ,	4.7	7
13	Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 411-417	5.3	5
12	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. <i>RMD Open</i> , 2020 , 6,	5.9	5
11	The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. <i>Rheumatology</i> , 2021 , 60, 4121-4129	3.8	4
10	Biomarkers of cardiovascular risk across phenotypes of osteoarthritis. <i>BMC Rheumatology</i> , 2019 , 3, 33	2.9	3
9	Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1512-1518	4.1	3
8	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. <i>Rheumatology</i> , 2021 , 60, 3635-3645	3.9	2
7	Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. <i>RMD Open</i> , 2020 , 6,	5.9	1
6	Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
5	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study. <i>Rheumatology</i> , 2021 , 60, 140-146	3.9	1
4	Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study. <i>Rheumatology</i> , 2021 , 60, 3656-3668	3.9	1
3	Trajectories of change in symptom severity in patients with fibromyalgia: exploratory analyses of a randomised controlled trial. <i>Rheumatology International</i> , 2021 , 41, 691-697	3.6	
2	Viral respiratory infections in patients treated with hydroxychloroquine. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 1146	2.2	
1	The referral of patients with fibromyalgia to a rheumatological specialist care unit. Is it necessary?. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 130, 194	2.2	

